These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

86 related articles for article (PubMed ID: 6666920)

  • 1. [Parkinson's disease and mental deterioration. Apropos of 30 cases].
    Mouren P; Poinso Y; Oppenheim G; Mouren A; Nguyen Quang N
    Ann Med Psychol (Paris); 1983 Nov; 141(9):945-56. PubMed ID: 6666920
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [A psychometric study of a group of Parkinsonian patients].
    Gil R; Lefevre JP
    Rev Neurol (Paris); 1980; 135(12):903-22. PubMed ID: 7466117
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Mental impairment in Parkinson's disease. The role of anticholinergic drugs.
    Meco G; Casacchia M; Lazzari R; Franzese A; Castellana F; Carta A; Iannuccelli M; Agnoli A
    Acta Psychiatr Belg; 1984; 84(4):325-35. PubMed ID: 6507124
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Sydney Multicenter Study of Parkinson's disease: non-L-dopa-responsive problems dominate at 15 years.
    Hely MA; Morris JG; Reid WG; Trafficante R
    Mov Disord; 2005 Feb; 20(2):190-9. PubMed ID: 15551331
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [A new levodopa benserazide preparation for Parkinson's disease with motor fluctuations refractory to standard L-dopa].
    Fernández Pardal MM; Gatto E; Micheli F; Casas Parera I; Diaz S
    Medicina (B Aires); 1991; 51(6):561-7. PubMed ID: 7476112
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Mental disorders in patients with Parkinson's disease treated with L-dopa].
    Piccirilli M; Piccinin GL
    Clin Ter; 1981 Jun; 97(5):473-9. PubMed ID: 7273659
    [No Abstract]   [Full Text] [Related]  

  • 7. Slowing of oscillatory brain activity is a stable characteristic of Parkinson's disease without dementia.
    Stoffers D; Bosboom JL; Deijen JB; Wolters EC; Berendse HW; Stam CJ
    Brain; 2007 Jul; 130(Pt 7):1847-60. PubMed ID: 17412733
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Mental disorders in Parkinson's disease after treatment with L-DOPA.
    Rondot P; de Recondo J; Coignet A; Ziegler M
    Adv Neurol; 1984; 40():259-69. PubMed ID: 6695602
    [No Abstract]   [Full Text] [Related]  

  • 9. [Intellectual impairments in patients with Parkinson's disease--a proposal of the subgroups of the disease].
    Nishimatsu O; Horiguchi J; Inami Y; Sukegawa T; Shoda M
    Rinsho Shinkeigaku; 1989 Oct; 29(10):1216-20. PubMed ID: 2605826
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Plasma homocysteine levels and Parkinson disease: disease progression, carotid intima-media thickness and neuropsychiatric complications.
    Hassin-Baer S; Cohen O; Vakil E; Sela BA; Nitsan Z; Schwartz R; Chapman J; Tanne D
    Clin Neuropharmacol; 2006; 29(6):305-11. PubMed ID: 17095893
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Hallucinations, delusions, and nocturnal events in 152 Parkinson's patients: a regional survey].
    Bailbé M; Karolewicz S; Neau JP; Dumas P; Gil R;
    Rev Neurol (Paris); 2002 Feb; 158(2):203-10. PubMed ID: 11965176
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Pramipexole vs levodopa as initial treatment for Parkinson disease: a 4-year randomized controlled trial.
    Holloway RG; Shoulson I; Fahn S; Kieburtz K; Lang A; Marek K; McDermott M; Seibyl J; Weiner W; Musch B; Kamp C; Welsh M; Shinaman A; Pahwa R; Barclay L; Hubble J; LeWitt P; Miyasaki J; Suchowersky O; Stacy M; Russell DS; Ford B; Hammerstad J; Riley D; Standaert D; Wooten F; Factor S; Jankovic J; Atassi F; Kurlan R; Panisset M; Rajput A; Rodnitzky R; Shults C; Petsinger G; Waters C; Pfeiffer R; Biglan K; Borchert L; Montgomery A; Sutherland L; Weeks C; DeAngelis M; Sime E; Wood S; Pantella C; Harrigan M; Fussell B; Dillon S; Alexander-Brown B; Rainey P; Tennis M; Rost-Ruffner E; Brown D; Evans S; Berry D; Hall J; Shirley T; Dobson J; Fontaine D; Pfeiffer B; Brocht A; Bennett S; Daigneault S; Hodgeman K; O'Connell C; Ross T; Richard K; Watts A;
    Arch Neurol; 2004 Jul; 61(7):1044-53. PubMed ID: 15262734
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Accuracy of acute levodopa challenge for clinical prediction of sustained long-term levodopa response as a major criterion for idiopathic Parkinson's disease diagnosis.
    Merello M; Nouzeilles MI; Arce GP; Leiguarda R
    Mov Disord; 2002 Jul; 17(4):795-8. PubMed ID: 12210878
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Behavioral indicators of hallucinosis in levodopa-treated Parkinson's disease.
    Glantz RH; Bieliauskas L; Paleologos N
    Adv Neurol; 1987; 45():417-20. PubMed ID: 3825719
    [No Abstract]   [Full Text] [Related]  

  • 15. [Benefit of L-DOPA-without-DCI (decarboxylase inhibitor) therapy on wearing-off phenomenon in advanced stages of Parkinson's disease patients].
    Hironishi M; Miwa H; Kondo T
    No To Shinkei; 2002 Feb; 54(2):127-32. PubMed ID: 11889758
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Response to L-dopa and evolution of motor fluctuations in the early phase of treatment of Parkinson's disease.
    Shif M; Kempster PA
    Clin Exp Neurol; 1994; 31():38-42. PubMed ID: 7586663
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Parkinson's disease, side affected and depression].
    Serrano-Dueñas M
    Rev Neurol; 2000 Dec 16-31; 31(12):1109-12. PubMed ID: 11205540
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Effects of L-DOPA on spatiotemporal contrast sensitivity in Parkinson's disease.
    Mestre DR; Blin O; van den Brand CL; Azulay JP; Serratrice G
    Adv Neurol; 1996; 69():503-11. PubMed ID: 8615172
    [No Abstract]   [Full Text] [Related]  

  • 19. Risk factors in development of motor complications in Chinese patients with idiopathic Parkinson's disease.
    Kum WF; Gao J; Durairajan SS; Man SC; Xie LX; Lu JH; Fong WL; Li M
    J Clin Neurosci; 2009 Aug; 16(8):1034-7. PubMed ID: 19428256
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A cerebrospinal fluid turnover in Parkinson's disease.
    Jamrozik Z; Królicki L; Kwieciński H; Florek M
    Mater Med Pol; 1996; 28(3):79-82. PubMed ID: 9167416
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.